MXPA01007952A - Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas. - Google Patents

Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.

Info

Publication number
MXPA01007952A
MXPA01007952A MXPA01007952A MXPA01007952A MXPA01007952A MX PA01007952 A MXPA01007952 A MX PA01007952A MX PA01007952 A MXPA01007952 A MX PA01007952A MX PA01007952 A MXPA01007952 A MX PA01007952A MX PA01007952 A MXPA01007952 A MX PA01007952A
Authority
MX
Mexico
Prior art keywords
methods
same
treating diseases
based formulations
arginine based
Prior art date
Application number
MXPA01007952A
Other languages
English (en)
Spanish (es)
Inventor
Wayne H Kaesemeyer
Original Assignee
Nitrosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitrosystems Inc filed Critical Nitrosystems Inc
Publication of MXPA01007952A publication Critical patent/MXPA01007952A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
MXPA01007952A 1999-02-05 2000-02-04 Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas. MXPA01007952A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11890399P 1999-02-05 1999-02-05
PCT/US2000/002798 WO2000045809A1 (fr) 1999-02-05 2000-02-04 Formulations a base de l-arginine utilisees dans le traitement de maladies, et leurs procedes d'utilisation

Publications (1)

Publication Number Publication Date
MXPA01007952A true MXPA01007952A (es) 2004-03-26

Family

ID=22381443

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01007952A MXPA01007952A (es) 1999-02-05 2000-02-04 Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.

Country Status (6)

Country Link
EP (1) EP1150669A4 (fr)
JP (1) JP2002536325A (fr)
AU (1) AU3356000A (fr)
CA (1) CA2361575A1 (fr)
MX (1) MXPA01007952A (fr)
WO (1) WO2000045809A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
US5968983A (en) 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
JP2002539257A (ja) 1999-03-19 2002-11-19 イーノス・ファーマシューティカルス・インコーポレーテッド 薬剤の脳内生物学的利用率の増加
JP5065570B2 (ja) * 2002-09-06 2012-11-07 第一三共ヘルスケア株式会社 血管内皮性酸化窒素の合成促進剤
EP1663339B1 (fr) * 2003-08-14 2013-07-31 Blue Medical Devices B.V. Prothese endoluminale comprenant un agent therapeutique
EP1591118A1 (fr) * 2004-04-27 2005-11-02 Nutri-Fit GmbH & Co. KG Utilisation de la mélatonine pour prévenir des complications postopératoires
JP2012041296A (ja) * 2010-08-19 2012-03-01 Medience Corp 血管内皮機能改善剤、一酸化窒素産生促進剤、及び飲食品

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758569A (en) * 1987-08-26 1988-07-19 Pfizer Inc. Doxazosin as an anti-atherosclerosis agent
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
WO1994009786A1 (fr) * 1992-11-04 1994-05-11 Sepracor, Inc. Procedes et compositions de doxazosine (+) utiles pour traiter l'hypertension
DE69432413T2 (de) * 1993-06-11 2004-05-13 The Board Of Trustees Of The Leland Stanford Junior University, Stanford Behandlung degenerativer gefaesserkrankungen durch modulation der endogenen stickoxidproduktion oder-aktivitaet
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
ES2224114T3 (es) * 1995-06-01 2005-03-01 N.V. Nutricia Composicion clinica nutricional.
FR2774593B1 (fr) * 1998-02-12 2000-05-05 Philippe Gorny Obtention d'un medicament destine a combattre les dysfonctions sexuelles feminines
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds

Also Published As

Publication number Publication date
AU3356000A (en) 2000-08-25
WO2000045809A1 (fr) 2000-08-10
EP1150669A4 (fr) 2005-06-22
JP2002536325A (ja) 2002-10-29
CA2361575A1 (fr) 2000-08-10
EP1150669A1 (fr) 2001-11-07

Similar Documents

Publication Publication Date Title
ATE376832T1 (de) Verzögert freisetzende formulierungen von oxymorphon
AU7031500A (en) Therapeutic quinazoline compounds
DE69722426D1 (de) Isobutylgaba und dessen derivate zur schmerzbehandlung
PL374865A1 (en) Treatment of tnf alpha related disorders
WO2003096990A3 (fr) Cages proteiques pour l'administration d'agents therapeutiques et d'imagerie medicale
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BG105534A (en) 5ht1 means and method for the treatment of migraine
PT998287E (pt) Utilizacao de levobupivacaina
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
AU2001249684A1 (en) Nasal administration of agents for the treatment of gastroparesis
HK1029944A1 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
MXPA01007952A (es) Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.
AU2002332488A8 (en) R-bambuterol, its preparation and therapeutic uses
GB9907571D0 (en) Compounds
MXPA02001204A (es) Compuestos calciliticos.
NO20005757L (no) Cabergolin og pramipexol - nye anvendelser og kombinasjoner
EP1671630A3 (fr) Formulations basées sur l-arginine pour le traitment des maladies et méthodes utilisants les memes
EP0904094A4 (fr) Traitement de maladies osseuses au moyen d'adrenomedulline
ES2159479A1 (es) Nuevos indazoles como inhibidores de la ciclooxigenasa-ii
AU5870298A (en) 1,4-dihydropyridin derivatives and their use in therapy
NZ523676A (en) Use of cetyl myristate and cetyl palmitate to treat irritable bowel syndrome or irritable bowel disease
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії
WO2003059334A3 (fr) Gemcitabine pour traiter la variole
UA10257A (uk) Спосіб фізіотерапевтичного впливу на організм людини